Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000236796 | SCV000292725 | uncertain significance | not specified | 2017-04-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001226919 | SCV001399248 | benign | Intellectual disability, autosomal dominant 6; Developmental and epileptic encephalopathy, 27 | 2024-04-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002450721 | SCV002612916 | uncertain significance | Inborn genetic diseases | 2020-03-20 | criteria provided, single submitter | clinical testing | The p.V1167I variant (also known as c.3499G>A), located in coding exon 12 of the GRIN2B gene, results from a G to A substitution at nucleotide position 3499. The valine at codon 1167 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and isoleucine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |